Adalta Ltd

Research Adalta Ltd (1AD) on Bullrun: market cap AUD 8.93M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker1AD
• ExchangeAU
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyAUD
• Market capAUD 8.93M
• Financial periodFY2025
• Net income-AUD 4.50M
• Free cash flow-AUD 2.94M

Valuation Snapshot

latest market cap is AUD 8.93M.

About Adalta Ltd

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration.

Frequently asked questions

What is Adalta Ltd's market cap?

Adalta Ltd's market capitalization is AUD 8.93M.

What does Adalta Ltd do?

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia.